Paul Lévesque will be appointed as President
and CEO, replacing Luc Tanguay, who
is retiring
MONTREAL, March 2, 2020 /PRNewswire/ - The board of
directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is
pleased to announce the appointment of Paul Lévesque as the
company's President and CEO, effective April
6, 2020, replacing Luc
Tanguay, who is retiring after a 23-year career. Mr. Tanguay
will remain available to ensure a smooth transition.
"Theratechnologies is at a turning point in its history. I am
extremely proud to join this team and leverage my knowledge and
expertise to ensure the company's continued growth, as well as to
harness its full potential," said Mr. Lévesque. "One of my main
goals is to bring Trogarzo to people living with HIV. Trogarzo,
whose approval has already been fast tracked, is a breakthrough
drug designed to meet an unmet medical need."
Paul Lévesque boasts over 30 years of experience in the
pharmaceutical field. After beginning his career in 1985 at UpJohn
in Montreal, he joined Pfizer
Canada in 1992, then Pfizer France in 2002, where he held various
positions, eventually serving as president of Pfizer Canada from
2007 to 2012. Since then, he has held several marketing and
executive positions at Pfizer headquarters in New York, as part of which he had
international responsibilities, notably in Asia-Pacific and in the United States. Mr. Lévesque is and will
remain the Global President of Pfizer Rare Disease until he takes
up his position at Theratechnologies.
"We are thrilled that Paul Lévesque is joining the company. On
behalf of the board and management, we look forward to working with
him and benefiting from his considerable experience in the global
commercialization of pharmaceutical products," said Dawn Svoronos, Chair of the Board of
Directors.
Theratechnologies would like to take this opportunity to
recognize the immense contribution of Luc
Tanguay, who skillfully led the company's critical
restructuring initiatives through his leadership and innovative
vision.
"On behalf of the board of directors, management and
shareholders, the company thanks Luc for his close collaboration
with board members and wishes him a well-deserved retirement,"
added Ms. Svoronos.
Mr. Tanguay, who has been involved in the biotechnology industry
for over 20 years, has been a member of the Theratechnologies
management team since 1996. As President and CEO since 2012, Mr.
Tanguay has transformed the company into a fully integrated
business operating in the United
States, Canada and
Europe, with a significant
research and development portfolio.
"It was an honour to be able to make a significant contribution
to the growth of Theratechnologies," said Mr. Tanguay. "I am proud
to leave Theratechnologies by handing over a company with a solid
infrastructure and financial health to my successor. I would like
to thank the loyal and high-performing management team members who
have contributed to the company's success over the past few years.
I have no doubt that they will be able to support Paul Lévesque and
help him build on this momentum."
ABOUT THERATECHNOLOGIES
Theratechnologies (TSX: TH)
(NASDAQ: THTX) is a commercial-stage biopharmaceutical company
addressing unmet medical needs by bringing to market specialized
therapies for people with orphan medical conditions, including
those living with HIV. Further information about Theratechnologies
is available on the Company's website at www.theratech.com, on
SEDAR at www.sedar.com and on EDGAR at www.sec.gov
View original content to download
multimedia:http://www.prnewswire.com/news-releases/change-to-theratechnologies-management-301014324.html
SOURCE Theratechnologies Inc.